跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 77 条关于
“TPM1”
全部
77
临床试验
52
药物
12
机构
0
资讯
13
7个月前
Nine-Marker Molecular Signature Identified as Driver of Lapatinib Resistance in HER2-Positive Breast Cancer
去年
Revumenib Shows Promise in Relapsed/Refractory NPM1-Mutated AML
去年
Revumenib Shows Promise in NPM1-Mutant AML: Pivotal Trial Results
去年
Ziftomenib Plus Intensive Induction Shows Promise in NPM1-Mutated AML
10个月前
FDA Approves Kura Oncology's Komzifti for NPM1-Mutated AML with Competitive Safety Advantage
去年
Bleximenib Shows Promising Results in Advanced Acute Leukemia Trial with KMT2A and NPM1 Mutations
9个月前
FDA Approves Ziftomenib, First-in-Class Targeted Therapy for NPM1-Mutated Acute Myeloid Leukemia
去年
Ziftomenib Shows Promise in Pivotal KOMET-001 Trial for Relapsed/Refractory NPM1-Mutant AML
去年
FDA Accepts Kura Oncology's NDA for Ziftomenib in NPM1-Mutant AML with Priority Review
10个月前
FDA Approves Komzifti as First Once-Daily Oral Menin Inhibitor for Relapsed NPM1-Mutated AML
第 1 页,共 2 页
上一页
下一页